Remdesivir reduces COVID-19 hospitalization or death risk in high-risk outpatients
Remdesivir may cut hospitalization risk for high-risk COVID outpatients
This Bayesian reanalysis of a Phase 3 RCT in high-risk outpatients with COVID-19 found a posterior median hazard ratio of 0.13 for COVID-19-…
A reanalysis of trial data suggests remdesivir sharply lowers the chance of hospitalization or death for high-risk COVID patients treated at…
Hospitalized COVID-19 patients receiving antiviral, antiretroviral, or immunosuppressive treatments showed variable outcomes.
What helps hospitalized COVID-19 patients survive? A new model offers clues.
This cohort study of 711 hospitalized subjects with coronavirus evaluated antiviral, antiretroviral, and immunosuppressive treatments. Resul…
When COVID-19 hits hard, doctors need better tools to predict who might get worse. A study of 711 hospitalized patients found that factors l…
Observational report describes racial and ethnic disparities in receiving COVID-19 treatment medications in the US
Report describes racial and ethnic disparities in receiving COVID-19 treatment medications
An observational report from the United States described racial and ethnic disparities in the receipt of medications for COVID-19 treatment.…
A new report describes racial and ethnic disparities in receiving medications for COVID-19 treatment in the United States.